{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:40:18Z","timestamp":1788381618423,"version":"build-2803163510"},"reference-count":22,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used in treating patients with EGFR-mutated non-small-cell lung cancers (NSCLCs), especially in cases with secondary resistance mutations. However, tertiary resistance mutations often arise, and there is currently no established standard of care for NSCLC harboring triple EGFR mutations. In recent years, brigatinib, an anaplastic lymphoma kinase (ALK) TKI, has shown effectiveness in treating EGFR triple-mutated NSCLC. Despite this, the combined use of osimertinib and brigatinib remains largely unstudied. This case report describes a 51-year-old woman with EGFR-mutated NSCLC who was initially treated with first- and second-generation EGFR TKIs, then switched to osimertinib upon development of an exon 20 T790M mutation. When an exon 20 C797S mutation emerged, the decision was made to add brigatinib to the osimertinib regimen. The combined treatment of osimertinib and brigatinib offers a promising new approach. Nonetheless, it is important to consider the potential risk of off-target toxicities.<\/jats:p>","DOI":"10.3390\/curroncol32050270","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:20:26Z","timestamp":1746591626000},"page":"270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report"],"prefix":"10.3390","volume":"32","author":[{"given":"Daphn\u00e9e","family":"Demers","sequence":"first","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3G 2M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Florescu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, QC H2X 0C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"ref_1","unstructured":"Statistics Canada (2024, January 28). Lung Cancer Is the Leading Cause of Cancer Death in Canada, Available online: https:\/\/www.statcan.gc.ca\/o1\/en\/plus\/238-lung-cancer-leading-cause-cancer-death-canada."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-019-0731-8","article-title":"Emerging therapies for non-small cell lung cancer","volume":"12","author":"Zhang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: Current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1002\/cam4.4336","article-title":"Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients","volume":"10","author":"Yang","year":"2021","journal-title":"Cancer Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.2147\/OTT.S170358","article-title":"Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: A case report","volume":"11","author":"Zhao","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_11","unstructured":"(2024, January 30). Clinical Guidance Report for Brigatinib. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2021\/10230BrigatinibALK%2BNSCLC_fnCGR_NOREDACT_EC21Apr2021_final.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Xing, P., Hao, X., Zhang, X., and Li, J. (2022). Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.920709"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Li, Y., Fu, R., Jiang, T., Duan, D., Wu, Y., Li, C., Li, Z., Ni, R., Li, L., and Liu, Y. (2022). Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.804212"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non\u2013Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Patil, P.D., and Panchabhai, T.S. (2020). Pulmonary Toxicities of Targeted Therapy. Handbook of Cancer Treatment-Related Symptoms and Toxicities, Elsevier. [1st ed.].","DOI":"10.1016\/B978-0-323-67241-2.00014-8"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e937209","DOI":"10.12659\/AJCR.937209","article-title":"Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858\/cisT790M\/cisC797S NSCLC: A Case Report","volume":"23","author":"Lee","year":"2022","journal-title":"Am. J. Case Rep."},{"key":"ref_18","unstructured":"(2024, November 15). LiverTox, Clinical and Research Information on Drug-Induced Liver Injury, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548523\/."},{"key":"ref_19","unstructured":"(2024, November 15). LiverTox, Clinical and Research Information on Drug-Induced Liver Injury, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548495\/."},{"key":"ref_20","unstructured":"(2023, November 29). Osimertinib. DrugBank. Available online: https:\/\/go.drugbank.com\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ctrv.2015.05.005","article-title":"Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review","volume":"41","author":"Hendriks","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41698-024-00542-9","article-title":"A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer","volume":"8","author":"Suzuki","year":"2024","journal-title":"NPJ Precis. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:28:18Z","timestamp":1760030898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["curroncol32050270"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32050270","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}